X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Orchid Chemicals with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ACTAVIS (US) - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ORCHID PHARMA LTD   ACTAVIS
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ACTAVIS
Dec-14
ORCHID PHARMA LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs19417,577-   
Low Rs3510,721-   
Sales per share (Unadj.) Rs276.53,165.0-  
Earnings per share (Unadj.) Rs-79.2-395.0-  
Cash flow per share (Unadj.) Rs-43.5290.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.96,864.9-  
Shares outstanding (eoy) m70.45265.90-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.5 9.3%   
Avg P/E ratio x-1.4-35.8 4.0%  
P/CF ratio (eoy) x-2.648.7 -5.4%  
Price / Book Value ratio x2.12.1 103.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0673,762,173 0.2%   
No. of employees `0002.821.6 13.0%   
Total wages/salary Rs m2,5270-   
Avg. sales/employee Rs Th6,956.138,962.3 17.9%   
Avg. wages/employee Rs Th902.50-   
Avg. net profit/employee Rs Th-1,993.0-4,862.1 41.0%   
INCOME DATA
Net Sales Rs m19,477841,585 2.3%  
Other income Rs m407-2,100 -19.4%   
Total revenues Rs m19,884839,484 2.4%   
Gross profit Rs m1,103108,114 1.0%  
Depreciation Rs m2,519182,234 1.4%   
Interest Rs m5,22726,545 19.7%   
Profit before tax Rs m-6,236-102,766 6.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-7,538 -6.8%   
Tax Rs m-125-5,283 2.4%   
Profit after tax Rs m-5,580-105,021 5.3%  
Gross profit margin %5.712.8 44.1%  
Effective tax rate %2.05.1 39.1%   
Net profit margin %-28.7-12.5 229.6%  
BALANCE SHEET DATA
Current assets Rs m11,014443,407 2.5%   
Current liabilities Rs m32,060323,374 9.9%   
Net working cap to sales %-108.114.3 -757.6%  
Current ratio x0.31.4 25.1%  
Inventory Days Days9558 163.5%  
Debtors Days Days3466 50.6%  
Net fixed assets Rs m29,440102,766 28.6%   
Share capital Rs m7050-   
"Free" reserves Rs m2,0430-   
Net worth Rs m3,8001,825,366 0.2%   
Long term debt Rs m9,018956,528 0.9%   
Total assets Rs m46,5103,345,296 1.4%  
Interest coverage x-0.2-2.9 6.7%   
Debt to equity ratio x2.40.5 452.9%  
Sales to assets ratio x0.40.3 166.5%   
Return on assets %-0.8-2.3 32.4%  
Return on equity %-146.9-5.8 2,552.5%  
Return on capital %-3.7-3.0 124.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Net fx Rs m1,8650-   
CASH FLOW
From Operations Rs m1,682144,516 1.2%  
From Investments Rs m-9,860-346,028 2.8%  
From Financial Activity Rs m6,644194,418 3.4%  
Net Cashflow Rs m-1,535-7,094 21.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.43 Rs / USD

Compare ORCHID PHARMA LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ORCHID PHARMA LTD With: NOVARTIS  SANOFI INDIA  DISHMAN PHARMA  LUPIN LTD  SHASUN PHARMA  



Today's Market

Indian Indices Continue to Fall, IT Sector Growth Projections, and Top Stocks in Action(Pre-Open)

On Wednesday, share markets in India opened in green but ended on a weak note. The BSE Sensex closed lower by 71 points to end the day at 33,704.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 20, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - FRESENIUS KABI ONCO. COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS